Clinical trials
catalyst calendar across sponsors →Studies where COYA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 6 tracked-famous managers (DME Capital Management, LP, MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Squarepoint Ops LLC, +1 more) · FINRA short interest 5.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of COYA 302 for the Treatment of ALSNCT07161999The change in disease progression as measured by the Revised ALS Functional Rating Scale (ALSFRS-R)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: COYA 302, Placebo | Amyotrophic Lateral Sclerosis (ALS) | 120 | Jan 2027 | ≤ 165 d | 2026-08-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19